BeOne MedicinesONC +1.65%81 PB Ratio is 6.54 as of Jun. 27, 2026, which is 12% above its 10-year median of 5.83. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $366.06 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, BeOne Medicines ranks worse than 77.76% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), BeOne Medicines's share price is $280.00. BeOne Medicines's Book Value per Share for the quarter that ended in Mar. 2026 was $42.83. Hence, BeOne Medicines's PB Ratio of today is 6.54.
Good Sign:
BeOne Medicines Ltd stock PB Ratio (=6.43) is close to 1-year low of 6.18.
The historical rank and industry rank for BeOne Medicines's PB Ratio or its related term are showing as below:
ONC'
s PB Ratio Range Over the Past 10 Years
Min: 2.31 Med: 5.83 Max: 13.38
Current: 6.53
During the past 13 years, BeOne Medicines's highest PB Ratio was 13.38. The lowest was 2.31. And the median was 5.83.
ONC's PB Ratio is ranked worse than 77.76% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ONC: 6.53
During the past 12 months, BeOne Medicines's average Book Value Per Share Growth Rate was 32.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -2.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BeOne Medicines was 42.10% per year. The lowest was -19.40% per year. And the median was 20.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BeOne Medicines PB Ratio Related Terms
BeOne Medicines PB Ratio Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's PB Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BeOne Medicines's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BeOne Medicines (ONC) has a PB Ratio of 6.54 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BeOne Medicines and its competitors. This is 12% above median its historical median of 5.83. Over the past decade, BeOne Medicines' PB Ratio has ranged from 2.31 to 13.38. According to the industry distribution chart, BeOne Medicines ranks #958 out of 1232 companies in the Biotechnology industry, placing it in the top 77.8%.
Is BeOne Medicines' PB Ratio too high?
BeOne Medicines' current PB Ratio of 6.54 is 12% above median its 10-year median of 5.83. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 13.38. The Biotechnology industry median PB Ratio is 2.80. BeOne Medicines' value of 6.54 is 133.6% above this industry median. Based on the distribution chart, BeOne Medicines ranks #958 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' PB Ratio compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #958 out of 1232 companies for PB Ratio. This places BeOne Medicines in the lower half of its industry. The industry median PB Ratio is 2.80. BeOne Medicines' value of 6.54 is 133.6% above this benchmark. Historically, BeOne Medicines' own PB Ratio has ranged from 2.31 to 13.38 over the past decade. While the company's 10-year median is 5.83 vs. the industry median of 2.80, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current PB Ratio of 6.54 is 133.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current PB Ratio is 6.54, which is 12% above median its own 10-year median of 5.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $280.00 — trading 23.5% below its estimated fair value. The current PB Ratio is 6.54, which is 12% above median its 10-year median of 5.83 and 133.6% above the Biotechnology industry median of 2.80. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BeOne Medicines (ONC), the current PB Ratio is 6.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
PB Ratio: 6.54 (12% above median its 10-year median of 5.83)
GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
Industry Position: 133.6% above the Biotechnology median (#958 of 1232)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for ONC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
